{"id": "article-27112_0", "title": "Phenobarbital -- Continuing Education Activity", "content": "Phenobarbital is a member of the barbiturate drug class that holds versatile therapeutic applications. This drug is effective in anti-seizure management, treatment for status epilepticus, and insomnia; it also plays a pivotal role in addressing benzodiazepine and alcohol withdrawal.\u00a0This mechanism\u00a0involves\u00a0interaction with GABA-A receptor subunits, facilitating the sustained opening of chloride ion gates and a continuous influx of ions into neuronal cells. By elongating the opening duration of chloride channels, phenobarbital induces a depression in the central nervous system.\u00a0The resultant hyperpolarization of the cell membrane elevates the action potential threshold, rendering phenobarbital an effective solution for seizure treatment. In the event of a phenobarbital overdose, a critical situation demanding coordinated efforts from the interprofessional team, this educational session meticulously examines its indications, mechanism of action, toxicity, contraindications, administration, adverse effects, and monitoring. The aim is to equip the interprofessional team with comprehensive insights for adeptly\u00a0managing\u00a0a phenobarbital overdose.", "contents": "Phenobarbital -- Continuing Education Activity. Phenobarbital is a member of the barbiturate drug class that holds versatile therapeutic applications. This drug is effective in anti-seizure management, treatment for status epilepticus, and insomnia; it also plays a pivotal role in addressing benzodiazepine and alcohol withdrawal.\u00a0This mechanism\u00a0involves\u00a0interaction with GABA-A receptor subunits, facilitating the sustained opening of chloride ion gates and a continuous influx of ions into neuronal cells. By elongating the opening duration of chloride channels, phenobarbital induces a depression in the central nervous system.\u00a0The resultant hyperpolarization of the cell membrane elevates the action potential threshold, rendering phenobarbital an effective solution for seizure treatment. In the event of a phenobarbital overdose, a critical situation demanding coordinated efforts from the interprofessional team, this educational session meticulously examines its indications, mechanism of action, toxicity, contraindications, administration, adverse effects, and monitoring. The aim is to equip the interprofessional team with comprehensive insights for adeptly\u00a0managing\u00a0a phenobarbital overdose."}
{"id": "article-27112_1", "title": "Phenobarbital -- Continuing Education Activity", "content": "Objectives: Identify appropriate indications for phenobarbital therapy based on patient-specific factors and clinical guidelines. Screen patients for contraindications and potential drug interactions before initiating phenobarbital therapy. Implement appropriate dosing regimens and administration techniques for phenobarbital, considering age, weight, and underlying medical conditions. Develop collaboration with other healthcare professionals, such as pharmacists and specialists, to ensure coordinated and comprehensive care for patients receiving phenobarbital therapy. Access free multiple choice questions on this topic.", "contents": "Phenobarbital -- Continuing Education Activity. Objectives: Identify appropriate indications for phenobarbital therapy based on patient-specific factors and clinical guidelines. Screen patients for contraindications and potential drug interactions before initiating phenobarbital therapy. Implement appropriate dosing regimens and administration techniques for phenobarbital, considering age, weight, and underlying medical conditions. Develop collaboration with other healthcare professionals, such as pharmacists and specialists, to ensure coordinated and comprehensive care for patients receiving phenobarbital therapy. Access free multiple choice questions on this topic."}
{"id": "article-27112_2", "title": "Phenobarbital -- Indications", "content": "Phenobarbital is a sedative-hypnotic agent\u00a0belonging to the barbiturates class of drugs. Phenobarbital has multiple clinical uses that include anti-seizure management. [1] Phenobarbital is also recommended as an\u00a0agent to treat status epilepticus. [2]", "contents": "Phenobarbital -- Indications. Phenobarbital is a sedative-hypnotic agent\u00a0belonging to the barbiturates class of drugs. Phenobarbital has multiple clinical uses that include anti-seizure management. [1] Phenobarbital is also recommended as an\u00a0agent to treat status epilepticus. [2]"}
{"id": "article-27112_3", "title": "Phenobarbital -- Indications", "content": "A study in China\u00a0compared valproic acid to phenobarbital to treat status epilepticus. Results showed that intravenous phenobarbital had better clinical outcomes in the study population\u00a0than valproic acid. [3] Although proven\u00a0effective for status epilepticus,\u00a0phenobarbital\u00a0has been\u00a0replaced with other drugs with less harmful side effects. [4] [2]", "contents": "Phenobarbital -- Indications. A study in China\u00a0compared valproic acid to phenobarbital to treat status epilepticus. Results showed that intravenous phenobarbital had better clinical outcomes in the study population\u00a0than valproic acid. [3] Although proven\u00a0effective for status epilepticus,\u00a0phenobarbital\u00a0has been\u00a0replaced with other drugs with less harmful side effects. [4] [2]"}
{"id": "article-27112_4", "title": "Phenobarbital -- Indications", "content": "Phenobarbital can also\u00a0be used\u00a0to\u00a0manage insomnia and apprehensiveness, although addiction is a point of concern when using phenobarbital for insomnia. This drug is also useful for\u00a0benzodiazepine and alcohol withdrawal\u00a0treatment\u00a0due to its anti-seizure properties and sedative effect. The syndrome resulting from alcohol withdrawal has a better clinical outcome\u00a0when treated with benzodiazepines, according\u00a0to significant evidence-based studies. [5] [6]", "contents": "Phenobarbital -- Indications. Phenobarbital can also\u00a0be used\u00a0to\u00a0manage insomnia and apprehensiveness, although addiction is a point of concern when using phenobarbital for insomnia. This drug is also useful for\u00a0benzodiazepine and alcohol withdrawal\u00a0treatment\u00a0due to its anti-seizure properties and sedative effect. The syndrome resulting from alcohol withdrawal has a better clinical outcome\u00a0when treated with benzodiazepines, according\u00a0to significant evidence-based studies. [5] [6]"}
{"id": "article-27112_5", "title": "Phenobarbital -- Indications", "content": "Long-acting agents such as phenobarbital are not the preferred option for surgical induction; short-acting barbiturates are commonly used for this indication. [7] Phenobarbital reduces intracranial pressure by suppressing cerebral metabolism in severe brain injury management. Still, phenobarbital's adverse effect of hypotension negatively impacts the brain's oxygen supply, thus offsetting any clinical benefit. [8]", "contents": "Phenobarbital -- Indications. Long-acting agents such as phenobarbital are not the preferred option for surgical induction; short-acting barbiturates are commonly used for this indication. [7] Phenobarbital reduces intracranial pressure by suppressing cerebral metabolism in severe brain injury management. Still, phenobarbital's adverse effect of hypotension negatively impacts the brain's oxygen supply, thus offsetting any clinical benefit. [8]"}
{"id": "article-27112_6", "title": "Phenobarbital -- Mechanism of Action", "content": "Phenobarbital increases the\u00a0duration of\u00a0time chloride channels are open, depressing\u00a0the central nervous system. This action occurs by acting on GABA-A receptor subunits. When phenobarbital binds to these receptors, the chloride ion gates open and stay open, allowing a steady flow\u00a0of these ions into neuronal cells. [1] This action\u00a0hyperpolarizes the cell membrane, increasing the action potential threshold.\u00a0This increase in action potential is why this drug is effective in treating\u00a0seizures.", "contents": "Phenobarbital -- Mechanism of Action. Phenobarbital increases the\u00a0duration of\u00a0time chloride channels are open, depressing\u00a0the central nervous system. This action occurs by acting on GABA-A receptor subunits. When phenobarbital binds to these receptors, the chloride ion gates open and stay open, allowing a steady flow\u00a0of these ions into neuronal cells. [1] This action\u00a0hyperpolarizes the cell membrane, increasing the action potential threshold.\u00a0This increase in action potential is why this drug is effective in treating\u00a0seizures."}
{"id": "article-27112_7", "title": "Phenobarbital -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Rapid and complete absorption occurs after oral or IV administration. [1] The time of peak plasma concentration ranges from\u00a030 minutes to 1\u00a0hour for oral formulations and is around 5 minutes for IV injection. Distribution: Rapidly distributed to all tissues and fluids. Metabolism: Metabolized primarily via acetylation in the liver (hepatic microsomal enzyme system). [1]", "contents": "Phenobarbital -- Mechanism of Action -- Pharmacokinetics. Absorption: Rapid and complete absorption occurs after oral or IV administration. [1] The time of peak plasma concentration ranges from\u00a030 minutes to 1\u00a0hour for oral formulations and is around 5 minutes for IV injection. Distribution: Rapidly distributed to all tissues and fluids. Metabolism: Metabolized primarily via acetylation in the liver (hepatic microsomal enzyme system). [1]"}
{"id": "article-27112_8", "title": "Phenobarbital -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: About 25% to 50% of the unchanged drug is excreted in the urine.\u00a0Remember that clearance rates vary with patients and their specific presentations. For instance,\u00a0patients who are terminally ill with cancer and on phenobarbital therapy may need dose adjustments due to reduced clearance of this drug. [9]", "contents": "Phenobarbital -- Mechanism of Action -- Pharmacokinetics. Elimination: About 25% to 50% of the unchanged drug is excreted in the urine.\u00a0Remember that clearance rates vary with patients and their specific presentations. For instance,\u00a0patients who are terminally ill with cancer and on phenobarbital therapy may need dose adjustments due to reduced clearance of this drug. [9]"}
{"id": "article-27112_9", "title": "Phenobarbital -- Administration -- Available Dosage Forms and Strengths", "content": "Phenobarbital administration is via a variety of routes. [10] These include: Oral Elixir: 20 mg/5 mL Oral Tablets: 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg, 100 mg Intramuscular (IM)/Intravenous (IV) Solution: 65 mg/mL, 130 mg/mL", "contents": "Phenobarbital -- Administration -- Available Dosage Forms and Strengths. Phenobarbital administration is via a variety of routes. [10] These include: Oral Elixir: 20 mg/5 mL Oral Tablets: 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg, 100 mg Intramuscular (IM)/Intravenous (IV) Solution: 65 mg/mL, 130 mg/mL"}
{"id": "article-27112_10", "title": "Phenobarbital -- Administration -- Available Dosage Forms and Strengths", "content": "Phenobarbital\u00a0should only be given\u00a0intravenously for emergency cases. If possible, other routes of administration\u00a0should be accessed first. When given IV, check for any indurations. Studies have shown that an induration at a\u00a0site of infusion results in a decreased bioavailability of phenobarbital. [11] Another study demonstrated the effectiveness of the rectal administration of phenobarbital, with a relative bioavailability reaching 90%. [12]", "contents": "Phenobarbital -- Administration -- Available Dosage Forms and Strengths. Phenobarbital\u00a0should only be given\u00a0intravenously for emergency cases. If possible, other routes of administration\u00a0should be accessed first. When given IV, check for any indurations. Studies have shown that an induration at a\u00a0site of infusion results in a decreased bioavailability of phenobarbital. [11] Another study demonstrated the effectiveness of the rectal administration of phenobarbital, with a relative bioavailability reaching 90%. [12]"}
{"id": "article-27112_11", "title": "Phenobarbital -- Administration -- Available Dosage Forms and Strengths", "content": "Patients can experience withdrawal symptoms if they stop taking the drug abruptly, so tapering off it is recommended. As per current guidelines from the American Epilepsy Society, generally, phenobarbital is given IV at 15 mg/kg in adult patients with status epilepticus. [13]", "contents": "Phenobarbital -- Administration -- Available Dosage Forms and Strengths. Patients can experience withdrawal symptoms if they stop taking the drug abruptly, so tapering off it is recommended. As per current guidelines from the American Epilepsy Society, generally, phenobarbital is given IV at 15 mg/kg in adult patients with status epilepticus. [13]"}
{"id": "article-27112_12", "title": "Phenobarbital -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: The manufacturer label provides no dose adjustment guidance for patients with hepatic impairment. However, phenobarbital is a potent inducer of cytochrome P450 enzymes, leading to interactions with other drugs by increasing their clearance.\u00a0Therefore, phenobarbital should be\u00a0used cautiously in patients with severe hepatic impairment.", "contents": "Phenobarbital -- Administration -- Specific Patient Populations. Hepatic impairment: The manufacturer label provides no dose adjustment guidance for patients with hepatic impairment. However, phenobarbital is a potent inducer of cytochrome P450 enzymes, leading to interactions with other drugs by increasing their clearance.\u00a0Therefore, phenobarbital should be\u00a0used cautiously in patients with severe hepatic impairment."}
{"id": "article-27112_13", "title": "Phenobarbital -- Administration -- Specific Patient Populations", "content": "Renal impairment: The manufacturer label does not provide dose adjustment guidance  for patients with\u00a0renal impairment. However, approximately 25% to 50% of phenobarbital is eliminated in the urine, so the drug should be used cautiously in patients with severe renal impairment.", "contents": "Phenobarbital -- Administration -- Specific Patient Populations. Renal impairment: The manufacturer label does not provide dose adjustment guidance  for patients with\u00a0renal impairment. However, approximately 25% to 50% of phenobarbital is eliminated in the urine, so the drug should be used cautiously in patients with severe renal impairment."}
{"id": "article-27112_14", "title": "Phenobarbital -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: Phenobarbital\u00a0is considered a pregnancy Category D medicine. Barbiturates are reported to cause fetal damage when administered to a pregnant female patient. No systematic and well-controlled studies have been reported for pregnant women. Maternal administration of barbiturates\u00a0reportedly has\u00a0a higher-than-expected incidence of fetal abnormality in retrospective, case-controlled studies.", "contents": "Phenobarbital -- Administration -- Specific Patient Populations. Pregnancy considerations: Phenobarbital\u00a0is considered a pregnancy Category D medicine. Barbiturates are reported to cause fetal damage when administered to a pregnant female patient. No systematic and well-controlled studies have been reported for pregnant women. Maternal administration of barbiturates\u00a0reportedly has\u00a0a higher-than-expected incidence of fetal abnormality in retrospective, case-controlled studies."}
{"id": "article-27112_15", "title": "Phenobarbital -- Administration -- Specific Patient Populations", "content": "Barbiturates, including phenobarbital, readily cross the placental barrier and are distributed throughout fetal tissues, and high concentrations are detected in the placenta, brain, and fetal liver. Withdrawal symptoms can occur in infants born to females who are administered barbiturates throughout the last trimester of pregnancy. If phenobarbital is administered during pregnancy or the patient gets pregnant while taking the drug. The patient should be informed and counseled about the potential hazard to the fetus. This drug should be used with caution only if needed during pregnancy. [14]", "contents": "Phenobarbital -- Administration -- Specific Patient Populations. Barbiturates, including phenobarbital, readily cross the placental barrier and are distributed throughout fetal tissues, and high concentrations are detected in the placenta, brain, and fetal liver. Withdrawal symptoms can occur in infants born to females who are administered barbiturates throughout the last trimester of pregnancy. If phenobarbital is administered during pregnancy or the patient gets pregnant while taking the drug. The patient should be informed and counseled about the potential hazard to the fetus. This drug should be used with caution only if needed during pregnancy. [14]"}
{"id": "article-27112_16", "title": "Phenobarbital -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: The manufacturer recommends caution for phenobarbital therapy in nursing mothers as the drug is present in breast milk. If infants' excessive drowsiness and poor weight gain are observed, limiting or discontinuing phenobarbital is also recommended. [15]", "contents": "Phenobarbital -- Administration -- Specific Patient Populations. Breastfeeding considerations: The manufacturer recommends caution for phenobarbital therapy in nursing mothers as the drug is present in breast milk. If infants' excessive drowsiness and poor weight gain are observed, limiting or discontinuing phenobarbital is also recommended. [15]"}
{"id": "article-27112_17", "title": "Phenobarbital -- Administration -- Specific Patient Populations", "content": "Pediatric patients: Reports indicate phenobarbital is associated with cognitive deficits in\u00a0pediatric\u00a0therapy for complicated febrile seizures. Using the dose as per the manufacturer's label is recommended.", "contents": "Phenobarbital -- Administration -- Specific Patient Populations. Pediatric patients: Reports indicate phenobarbital is associated with cognitive deficits in\u00a0pediatric\u00a0therapy for complicated febrile seizures. Using the dose as per the manufacturer's label is recommended."}
{"id": "article-27112_18", "title": "Phenobarbital -- Administration -- Specific Patient Populations", "content": "Older patients: The safety and efficacy of phenobarbital are not systematically studied in\u00a0older patients. However, it is recommended to use the drug cautiously as it may cause excitement, depression, or confusion in some\u00a0older patients.", "contents": "Phenobarbital -- Administration -- Specific Patient Populations. Older patients: The safety and efficacy of phenobarbital are not systematically studied in\u00a0older patients. However, it is recommended to use the drug cautiously as it may cause excitement, depression, or confusion in some\u00a0older patients."}
{"id": "article-27112_19", "title": "Phenobarbital -- Adverse Effects", "content": "Complications associated with phenobarbital use\u00a0include coma, impaired breathing effort, low blood pressure, incoordination, poor balance, and drowsiness. [1] These adverse effects, stemming from phenobarbital usage, impact\u00a0older patients to a greater degree. Therefore, newer\u00a0antiepileptics (lamotrigine, levetiracetam)\u00a0are preferred as seizure treatment in this patient population. [16]", "contents": "Phenobarbital -- Adverse Effects. Complications associated with phenobarbital use\u00a0include coma, impaired breathing effort, low blood pressure, incoordination, poor balance, and drowsiness. [1] These adverse effects, stemming from phenobarbital usage, impact\u00a0older patients to a greater degree. Therefore, newer\u00a0antiepileptics (lamotrigine, levetiracetam)\u00a0are preferred as seizure treatment in this patient population. [16]"}
{"id": "article-27112_20", "title": "Phenobarbital -- Adverse Effects", "content": "When used long-term, adverse events of phenobarbital include irritability, loss of appetite, achiness in the bones, joints, or muscles, depression, and, rarely, liver damage. [1] When taking barbiturates such as phenobarbital,\u00a0patients may\u00a0experience withdrawal symptoms if they stop taking the drug abruptly; tapering off the medication is necessary. In post-marketing surveillance of hospitalized patients using phenobarbital, the following adverse reactions have\u00a0been\u00a0reported:", "contents": "Phenobarbital -- Adverse Effects. When used long-term, adverse events of phenobarbital include irritability, loss of appetite, achiness in the bones, joints, or muscles, depression, and, rarely, liver damage. [1] When taking barbiturates such as phenobarbital,\u00a0patients may\u00a0experience withdrawal symptoms if they stop taking the drug abruptly; tapering off the medication is necessary. In post-marketing surveillance of hospitalized patients using phenobarbital, the following adverse reactions have\u00a0been\u00a0reported:"}
{"id": "article-27112_21", "title": "Phenobarbital -- Adverse Effects", "content": "Nervous system: Agitation, somnolence, confusion, CNS depression, hyperkinesia, ataxia,\u00a0 nervousness, nightmares, psychiatric disturbance,\u00a0 thinking abnormality, insomnia, anxiety, hallucinations, dizziness Respiratory: Apnea, hypoventilation Cardiovascular: Hypotension, bradycardia, syncope Gastrointestinal: Nausea, vomiting, constipation Dermatologic: Exfoliative dermatitis, toxic epidermic necrolysis,\u00a0Stevens-Johnson syndrome (rare) Others: Headache; hypersensitivity reactions, including but not limited to angioedema and skin rashes, injection site reactions, fever, liver damage and megaloblastic anemia in chronic users", "contents": "Phenobarbital -- Adverse Effects. Nervous system: Agitation, somnolence, confusion, CNS depression, hyperkinesia, ataxia,\u00a0 nervousness, nightmares, psychiatric disturbance,\u00a0 thinking abnormality, insomnia, anxiety, hallucinations, dizziness Respiratory: Apnea, hypoventilation Cardiovascular: Hypotension, bradycardia, syncope Gastrointestinal: Nausea, vomiting, constipation Dermatologic: Exfoliative dermatitis, toxic epidermic necrolysis,\u00a0Stevens-Johnson syndrome (rare) Others: Headache; hypersensitivity reactions, including but not limited to angioedema and skin rashes, injection site reactions, fever, liver damage and megaloblastic anemia in chronic users"}
{"id": "article-27112_22", "title": "Phenobarbital -- Contraindications", "content": "Phenobarbital is contraindicated in patients with known barbiturate sensitivity. Barbiturates, including phenobarbital, are contraindicated in patients with a history of latent porphyria, liver impairment, and large doses in patients with nephritic syndrome. Phenobarbital should not be given to persons with a known history of addiction to sedative-hypnotic medicines. Injectable preparation should not be given via intraarterial or subcutaneous routes.", "contents": "Phenobarbital -- Contraindications. Phenobarbital is contraindicated in patients with known barbiturate sensitivity. Barbiturates, including phenobarbital, are contraindicated in patients with a history of latent porphyria, liver impairment, and large doses in patients with nephritic syndrome. Phenobarbital should not be given to persons with a known history of addiction to sedative-hypnotic medicines. Injectable preparation should not be given via intraarterial or subcutaneous routes."}
{"id": "article-27112_23", "title": "Phenobarbital -- Contraindications", "content": "Phenobarbital is a potent cytochrome P450 inducer, so careful consideration is necessary when given concurrently with other medications. For instance, a woman with epilepsy who takes oral contraceptive pills and phenobarbital at the same time must be fully aware of the possible\u00a0interaction between the medications. Phenobarbital is known to induce the liver's cytochrome p450 enzymes, speeding up the metabolism of estrogens and progestins. Thus, a woman taking both antiepileptic medication and oral contraceptive pills\u00a0may experience an unexpected pregnancy due to the decreased efficacy of her oral contraceptive pills. [17] Patients taking warfarin must have close monitoring of INR due to drug interactions.", "contents": "Phenobarbital -- Contraindications. Phenobarbital is a potent cytochrome P450 inducer, so careful consideration is necessary when given concurrently with other medications. For instance, a woman with epilepsy who takes oral contraceptive pills and phenobarbital at the same time must be fully aware of the possible\u00a0interaction between the medications. Phenobarbital is known to induce the liver's cytochrome p450 enzymes, speeding up the metabolism of estrogens and progestins. Thus, a woman taking both antiepileptic medication and oral contraceptive pills\u00a0may experience an unexpected pregnancy due to the decreased efficacy of her oral contraceptive pills. [17] Patients taking warfarin must have close monitoring of INR due to drug interactions."}
{"id": "article-27112_24", "title": "Phenobarbital -- Contraindications", "content": "Patients with underlying obstructive lung disease will have an increased risk of complications. [1] The\u00a0depression of the respiratory system associated with barbiturate toxicity compounded with an already compromised respiratory system can contribute\u00a0to complications.\u00a0Research has\u00a0also\u00a0found that the drug interaction from combined oral theophylline medication\u00a0and phenobarbital negatively impacted theophylline blood levels compared to plain oral theophylline pills.\u00a0Phenobarbital has shown a capacity to decrease levels of steroids and theophylline via the cytochrome p450 liver metabolism system. [18] Therefore, patients receiving combined oral therapy for their lung condition may experience issues with\u00a0subtherapeutic blood levels of corticosteroids or theophylline.", "contents": "Phenobarbital -- Contraindications. Patients with underlying obstructive lung disease will have an increased risk of complications. [1] The\u00a0depression of the respiratory system associated with barbiturate toxicity compounded with an already compromised respiratory system can contribute\u00a0to complications.\u00a0Research has\u00a0also\u00a0found that the drug interaction from combined oral theophylline medication\u00a0and phenobarbital negatively impacted theophylline blood levels compared to plain oral theophylline pills.\u00a0Phenobarbital has shown a capacity to decrease levels of steroids and theophylline via the cytochrome p450 liver metabolism system. [18] Therefore, patients receiving combined oral therapy for their lung condition may experience issues with\u00a0subtherapeutic blood levels of corticosteroids or theophylline."}
{"id": "article-27112_25", "title": "Phenobarbital -- Contraindications", "content": "Abstinence\u00a0from alcohol while taking barbiturates is crucial because of the danger of severe respiratory depression\u00a0when both drugs are in the patient's system. When taken simultaneously, both drugs' individual\u00a0effects\u00a0on\u00a0GABA-A are additive, potentially resulting in\u00a0a life-threatening scenario. [1]", "contents": "Phenobarbital -- Contraindications. Abstinence\u00a0from alcohol while taking barbiturates is crucial because of the danger of severe respiratory depression\u00a0when both drugs are in the patient's system. When taken simultaneously, both drugs' individual\u00a0effects\u00a0on\u00a0GABA-A are additive, potentially resulting in\u00a0a life-threatening scenario. [1]"}
{"id": "article-27112_26", "title": "Phenobarbital -- Monitoring", "content": "Phenobarbital's effective dosage is between 10 to 40 \u03bcg/mL. Once blood levels exceed\u00a040 \u03bcg/mL, the patient is in a lethal range and at substantial risk. [1]", "contents": "Phenobarbital -- Monitoring. Phenobarbital's effective dosage is between 10 to 40 \u03bcg/mL. Once blood levels exceed\u00a040 \u03bcg/mL, the patient is in a lethal range and at substantial risk. [1]"}
{"id": "article-27112_27", "title": "Phenobarbital -- Toxicity", "content": "Barbiturate toxicity is noticeable at 1 g orally, although this varies\u00a0depending on the individual. Doses above 2 g can result in death, but\u00a0the deadly\u00a0dose usually is\u00a0between 40\u00a0and 80 \u03bcg/mL. [1]", "contents": "Phenobarbital -- Toxicity. Barbiturate toxicity is noticeable at 1 g orally, although this varies\u00a0depending on the individual. Doses above 2 g can result in death, but\u00a0the deadly\u00a0dose usually is\u00a0between 40\u00a0and 80 \u03bcg/mL. [1]"}
{"id": "article-27112_28", "title": "Phenobarbital -- Toxicity -- Signs and Symptoms of Overdose", "content": "Toxicity from barbiturates varies, but common symptoms include\u00a0the following: Cognitive impairment Decreased heart rate Incoordination Nausea Muscle weakness Polydipsia Below-normal urine output Decreased body temperature Mydriasis Deaths have occurred due to respiratory depression, hypotension, and coma. [1]", "contents": "Phenobarbital -- Toxicity -- Signs and Symptoms of Overdose. Toxicity from barbiturates varies, but common symptoms include\u00a0the following: Cognitive impairment Decreased heart rate Incoordination Nausea Muscle weakness Polydipsia Below-normal urine output Decreased body temperature Mydriasis Deaths have occurred due to respiratory depression, hypotension, and coma. [1]"}
{"id": "article-27112_29", "title": "Phenobarbital -- Toxicity -- Management of Overdose", "content": "Phenobarbital overdose is a healthcare emergency and requires teamwork from the entire healthcare spectrum to help the patient.\u00a0The healthcare team must implement the management of cardiac and respiratory status quickly. [1] [19] Alkalinizing the urine can help eliminate the drug, but if prior interventions fail to advance patients in a positive direction,\u00a0hemodialysis or hemoperfusion can expedite drug clearance. [1] [20] [21]", "contents": "Phenobarbital -- Toxicity -- Management of Overdose. Phenobarbital overdose is a healthcare emergency and requires teamwork from the entire healthcare spectrum to help the patient.\u00a0The healthcare team must implement the management of cardiac and respiratory status quickly. [1] [19] Alkalinizing the urine can help eliminate the drug, but if prior interventions fail to advance patients in a positive direction,\u00a0hemodialysis or hemoperfusion can expedite drug clearance. [1] [20] [21]"}
{"id": "article-27112_30", "title": "Phenobarbital -- Toxicity -- Management of Overdose", "content": "Hemoperfusion\u00a0was\u00a0thought to be\u00a0more effective in phenobarbital overdose\u00a0due to increased protein binding; however, a case of severe phenobarbital intoxication treated with high-efficiency dialyzers and increased rates of blood flow showed that hemodialysis is the better option for drug clearance in compromised patients. The patient experienced a positive clinical outcome after phenobarbital levels dropped rapidly. [20]", "contents": "Phenobarbital -- Toxicity -- Management of Overdose. Hemoperfusion\u00a0was\u00a0thought to be\u00a0more effective in phenobarbital overdose\u00a0due to increased protein binding; however, a case of severe phenobarbital intoxication treated with high-efficiency dialyzers and increased rates of blood flow showed that hemodialysis is the better option for drug clearance in compromised patients. The patient experienced a positive clinical outcome after phenobarbital levels dropped rapidly. [20]"}
{"id": "article-27112_31", "title": "Phenobarbital -- Toxicity -- Recommendations", "content": "Treatment of phenobarbital toxicity is supportive, comprising\u00a0maintenance of airway function (through endotracheal intubation and mechanical ventilation), correction of bradycardia, and hypotension (with IV fluids and vasopressors, if necessary). [18]", "contents": "Phenobarbital -- Toxicity -- Recommendations. Treatment of phenobarbital toxicity is supportive, comprising\u00a0maintenance of airway function (through endotracheal intubation and mechanical ventilation), correction of bradycardia, and hypotension (with IV fluids and vasopressors, if necessary). [18]"}
{"id": "article-27112_32", "title": "Phenobarbital -- Toxicity -- Recommendations", "content": "After properly evaluating and correcting the patient's airway, breathing, and circulation, removing the drug from the body is\u00a0imperative; this can occur via gastric irrigation,\u00a0forced alkaline diuresis,\u00a0or dialysis. [20] A specific treatment does not currently exist. [1]", "contents": "Phenobarbital -- Toxicity -- Recommendations. After properly evaluating and correcting the patient's airway, breathing, and circulation, removing the drug from the body is\u00a0imperative; this can occur via gastric irrigation,\u00a0forced alkaline diuresis,\u00a0or dialysis. [20] A specific treatment does not currently exist. [1]"}
{"id": "article-27112_33", "title": "Phenobarbital -- Enhancing Healthcare Team Outcomes", "content": "Phenobarbital is a class IV control substance, and it is used\u00a0for\u00a0its\u00a0sedative and anti-seizure properties in patients with status epileptics and alcohol withdrawal management. However, it is no longer a first-line agent. Phenobarbital is known for being highly addictive and was historically a common agent of choice for suicide attempts. [19] Phenobarbital is a drug that\u00a0poses an emergent\u00a0situation for the interprofessional healthcare\u00a0team when a patient\u00a0arrives\u00a0after an attempted or accidental overdose.", "contents": "Phenobarbital -- Enhancing Healthcare Team Outcomes. Phenobarbital is a class IV control substance, and it is used\u00a0for\u00a0its\u00a0sedative and anti-seizure properties in patients with status epileptics and alcohol withdrawal management. However, it is no longer a first-line agent. Phenobarbital is known for being highly addictive and was historically a common agent of choice for suicide attempts. [19] Phenobarbital is a drug that\u00a0poses an emergent\u00a0situation for the interprofessional healthcare\u00a0team when a patient\u00a0arrives\u00a0after an attempted or accidental overdose."}
{"id": "article-27112_34", "title": "Phenobarbital -- Enhancing Healthcare Team Outcomes", "content": "Although restrictions on access to barbiturates have\u00a0led to a decline in\u00a0the number of overdoses, expeditiously assessing and treating patients with a phenobarbital overdose is still crucial. [1] In case of a suspected drug overdose, the healthcare team must\u00a0evaluate the patient's vitals and ensure optimal respiratory effort. If\u00a0respiration is compromised, precautions for respiratory support must be\u00a0implemented (endotracheal intubation or mechanical ventilation). As a next step, urine or blood toxicology is necessary\u00a0to confirm the suspected diagnosis.", "contents": "Phenobarbital -- Enhancing Healthcare Team Outcomes. Although restrictions on access to barbiturates have\u00a0led to a decline in\u00a0the number of overdoses, expeditiously assessing and treating patients with a phenobarbital overdose is still crucial. [1] In case of a suspected drug overdose, the healthcare team must\u00a0evaluate the patient's vitals and ensure optimal respiratory effort. If\u00a0respiration is compromised, precautions for respiratory support must be\u00a0implemented (endotracheal intubation or mechanical ventilation). As a next step, urine or blood toxicology is necessary\u00a0to confirm the suspected diagnosis."}
{"id": "article-27112_35", "title": "Phenobarbital -- Enhancing Healthcare Team Outcomes", "content": "While in recovery, patients require counsel\u00a0about barbiturates and proper\u00a0use. [1] This educational opportunity and a psychiatric evaluation are pertinent for the patient. Regarding preventing future overdoses, an interprofessional effort among patients' healthcare providers is necessary to\u00a0ensure that the patient is not prescribed many pills at once. Prescribers can also evaluate whether the patient can be switched to an alternative medication.", "contents": "Phenobarbital -- Enhancing Healthcare Team Outcomes. While in recovery, patients require counsel\u00a0about barbiturates and proper\u00a0use. [1] This educational opportunity and a psychiatric evaluation are pertinent for the patient. Regarding preventing future overdoses, an interprofessional effort among patients' healthcare providers is necessary to\u00a0ensure that the patient is not prescribed many pills at once. Prescribers can also evaluate whether the patient can be switched to an alternative medication."}
{"id": "article-27112_36", "title": "Phenobarbital -- Enhancing Healthcare Team Outcomes", "content": "A cohort study showed that subjects who purposely overdosed on barbiturates showed an increased risk of an adverse ICU course. If clinicians judiciously prescribe\u00a0barbiturates, the patient is less likely to overdose and thus less likely to\u00a0have an unfavorable hospital course. [22] Nurses should check for vitals and any adverse reactions at all visits; they must be aware of the signs of toxicity or misuse to alert the prescriber. Pharmacists should verify phenobarbital's dose, duration, and drug interactions and inform prescribers of any concerns.", "contents": "Phenobarbital -- Enhancing Healthcare Team Outcomes. A cohort study showed that subjects who purposely overdosed on barbiturates showed an increased risk of an adverse ICU course. If clinicians judiciously prescribe\u00a0barbiturates, the patient is less likely to overdose and thus less likely to\u00a0have an unfavorable hospital course. [22] Nurses should check for vitals and any adverse reactions at all visits; they must be aware of the signs of toxicity or misuse to alert the prescriber. Pharmacists should verify phenobarbital's dose, duration, and drug interactions and inform prescribers of any concerns."}
{"id": "article-27112_37", "title": "Phenobarbital -- Enhancing Healthcare Team Outcomes", "content": "In summary, the management of therapy with phenobarbital is the responsibility of the interprofessional healthcare team, including clinicians, specialists, pharmacists, and mental health practitioners, operating as a cohesive unit to optimize treatment outcomes and prevent mortality and morbidity from phenobarbital misuse.", "contents": "Phenobarbital -- Enhancing Healthcare Team Outcomes. In summary, the management of therapy with phenobarbital is the responsibility of the interprofessional healthcare team, including clinicians, specialists, pharmacists, and mental health practitioners, operating as a cohesive unit to optimize treatment outcomes and prevent mortality and morbidity from phenobarbital misuse."}
{"id": "article-27112_38", "title": "Phenobarbital -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Phenobarbital -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}